FDA Approves Novo Nordisk\'s Esperoct To Treat Haemophilia A

FDA Approves Novo Nordisk's Esperoct To Treat Haemophilia A

21:52 EST 19 Feb 2019 | FinanzNachrichten

WASHINGTON (dpa-AFX) - Novo Nordisk announced that the US Food and Drug Administration has approved the Biologics License Application for Esperoct for the treatment of adults and children with hae...

Original Article: FDA Approves Novo Nordisk's Esperoct To Treat Haemophilia A

More From BioPortfolio on "FDA Approves Novo Nordisk's Esperoct To Treat Haemophilia A"